BEXSERO 25 MCG / 0.5 ML
OUTER MEMBRANE VESICLES (NEISSERIA MENINGITIDIS GROUP B NZ98/254 STRAIN) : 25 MCG / 0.5 ML RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN : 50 MCG / 0.5 ML RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN : 50 MCG / 0.5 ML RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN : 50 MCG / 0.5 ML · DIN 02417030 · GLAXOSMITHKLINE INC
Health Canada status: MARKETED
What is BEXSERO?
BEXSERO 25 MCG / 0.5 ML contains OUTER MEMBRANE VESICLES (NEISSERIA MENINGITIDIS GROUP B NZ98/254 STRAIN) : 25 MCG / 0.5 ML RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN : 50 MCG / 0.5 ML RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN : 50 MCG / 0.5 ML RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN : 50 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02417030, held by GLAXOSMITHKLINE INC, supplied as SUSPENSION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 08-Sep-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02417030 |
|---|---|
| Brand name | BEXSERO |
| Generic / active ingredient | OUTER MEMBRANE VESICLES (NEISSERIA MENINGITIDIS GROUP B NZ98/254 STRAIN) : 25 MCG / 0.5 ML RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN : 50 MCG / 0.5 ML RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN : 50 MCG / 0.5 ML RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN : 50 MCG / 0.5 ML |
| Manufacturer | GLAXOSMITHKLINE INC |
| Strength | 25 MCG / 0.5 ML |
| Dosage form | SUSPENSION |
| Route of administration | INTRAMUSCULAR |
| Schedule | Schedule D |
| ATC code | J07AH09 MENINGOCOCCUS B, MULTICOMPONENT VACCINE |
| AHFS class | 12:04.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 08-Sep-2016 |
| Original market date | 2013-12-05 00:00:00 |
Who else supplies MENINGOCOCCUS B, MULTICOMPONENT VACCINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MENINGOCOCCUS B, MULTICOMPONENT VACCINE appears in 4 registered pack listings across 4 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.